India Pharmaceutical Market, By Region, Competition, Forecast and Opportunities, 2020-2030F

India Pharmaceutical Market was valued at USD 65.20 Billion in 2024 and is expected to reach USD 106.67 Billion by 2030 with a CAGR of 8.75% during the forecast period. This expansion is largely attributed to the country’s robust domestic market and its prominence as a global hub for pharmaceutical manufacturing and innovation. The domestic market benefits from a growing middle class, increased healthcare awareness, and significant government initiatives aimed at improving healthcare access and infrastructure. For instance, programs like the Pradhan Mantri Jan Arogya Yojana (PMJAY) are designed to provide health coverage to economically disadvantaged segments, thereby boosting demand for pharmaceuticals.

In addition to domestic growth, India has established itself as a major player in the global pharmaceutical industry, particularly through its export of generic medicines. Indian pharmaceutical companies supply over 60% of the world's vaccines and approximately 20% of generic drugs, demonstrating their capability to provide high-quality, cost-effective solutions on a global scale. This position has been reinforced by the country's competitive advantage in the production of generics, which helps meet global healthcare needs at affordable prices.

Despite its impressive growth, the Indian pharmaceutical market faces several challenges that could impact its future trajectory. One of the primary issues is the complex regulatory environment. The Central Drugs Standard Control Organization (CDSCO) is responsible for overseeing drug regulation in India, and while efforts have been made to streamline processes, navigating regulatory requirements remains a challenge for many companies. Compliance with stringent regulations is necessary to ensure the safety and efficacy of pharmaceuticals, but it can also create barriers to entry and increase operational costs.

Another significant challenge is the issue of price controls. The Indian government imposes price controls on essential drugs to make healthcare affordable for the masses. While this policy aims to benefit consumers, it can also affect the profitability of pharmaceutical companies and their capacity to invest in research and development. Price controls can constrain revenue growth and limit the resources available for innovation and expansion.

Key Market Drivers

Growing Prevalence of Chronic Diseases

The Indian pharmaceutical market is witnessing robust growth, driven significantly by the escalating prevalence of chronic diseases. This trend is reshaping the healthcare landscape and creating substantial opportunities for pharmaceutical companies. Chronic diseases such as diabetes, cardiovascular conditions, chronic respiratory diseases, and cancer are becoming increasingly common in India, presenting both challenges and prospects for the pharmaceutical industry.

Chronic diseases are becoming a leading health concern in India, reflecting global patterns of non-communicable diseases (NCDs). According to the World Health Organization (WHO), NCDs account for a significant proportion of the total disease burden in India, with conditions like diabetes and cardiovascular diseases leading the list. According to a report released by Medlr in June 2023, a study published by the Indian Journal of Medical Research has revealed that 7.5% of adults aged 30-74 are affected by cardiovascular diseases (CVDs). The study also highlights that hypertension, a major risk factor for CVDs, is prevalent in 29.8% of the population within this age group. Additionally, diabetes, a chronic condition that impairs the body's ability to process blood sugar, is expected to impact 134 million individuals in India by 2045, up from the current estimate of 77 million. The increasing prevalence of these chronic conditions can be attributed to various factors, including lifestyle changes, urbanization, and an aging population. Sedentary lifestyles, poor dietary habits, and increased stress levels contribute to the rising incidence of chronic diseases, which in turn drives demand for effective pharmaceutical interventions.

Diabetes, for instance, has become a major public health challenge in India. The International Diabetes Federation estimates that India has the highest number of diabetic patients in the world, with numbers expected to continue rising. In India, diabetes is predominantly Type 2, accounting for 90% of all cases. This form of diabetes is particularly prevalent among individuals who are overweight, lead a sedentary lifestyle, consume a diet high in refined carbohydrates and saturated fats, and have a family history of the condition. Similarly, cardiovascular diseases are responsible for a substantial portion of deaths in India, driven by risk factors such as hypertension, obesity, and smoking. Chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, are also prevalent, exacerbated by environmental pollution and lifestyle factors. The increase in cancer cases, with types such as breast, lung, and colorectal cancer becoming more common, further underscores the growing burden of chronic diseases.

The rising prevalence of chronic diseases has a direct and profound impact on the pharmaceutical market in India. As the number of individuals affected by chronic conditions grows, so does the demand for medications and treatments designed to manage these long-term health issues. Pharmaceutical companies are responding to this increased demand by focusing on the development and commercialization of drugs that address chronic conditions effectively. In India, many patients seeking treatment for acute or chronic conditions face a significant challenge in accessing essential medications. The country experiences some of the highest out-of-pocket expenses (OOPE) for healthcare, with drugs accounting for over 67% of these costs, according to the NSSO's 68th round survey. Recognizing the critical need for access to essential drugs, the Ministry of Health & Family Welfare has launched the "Free Drugs Service Initiative" (FDSI) under the National Health Mission (NHM). This initiative includes operational guidelines and model RFPs shared with states, alongside the budget allocation. The guidelines focus on procuring generic essential medicines at reduced prices, eliminating irrational medications, and avoiding unscientific fixed-dose combinations.

For instance, the market for diabetes medications has expanded significantly, with a wide range of antidiabetic drugs being introduced to meet diverse patient needs. Similarly, the cardiovascular drug market is evolving with advancements in medications that address hypertension, hyperlipidemia, and other cardiovascular risk factors. The rise in demand for cancer therapies, including targeted therapies and immunotherapies, is also creating opportunities for pharmaceutical companies to innovate and offer new solutions. In July 2024, Eli Lilly and Co. achieved a significant milestone by obtaining the first approvals for the import and sale of a weight-loss medication in India, surpassing its competitor, Novo Nordisk AS. Eli Lilly will market this medication under the brand names Zepbound and Mountjaro, both of which are chemically known as tirzepatide. While these drugs were primarily developed for the treatment of type 2 diabetes, they are also approved for weight loss management.

The increasing burden of chronic diseases has also driven investment in research and development (R&D) within the pharmaceutical industry. Companies are investing heavily in R&D to discover novel therapies, improve existing treatments, and enhance patient outcomes. The focus on personalized medicine and precision healthcare is gaining momentum, aiming to provide tailored treatments based on individual patient profiles and genetic information. This trend is expected to continue as pharmaceutical firms seek to address the specific needs of patients with chronic conditions.

Rise in Generic Drug Industry

India’s pharmaceutical industry stands as a colossal force in the global healthcare landscape, with the generic drug sector playing a pivotal role in its remarkable growth. The rise of the generic drug industry is not merely a facet of the Indian pharmaceutical market but a significant driver shaping its trajectory. This sector's expansion is catalyzing India's emergence as a global hub for affordable and accessible medication, and its influence on the domestic market is profound and multifaceted.

According to a report by the Times of India published in March 2023, the global market for generic drugs, valued at USD 390.57 billion in 2020, is anticipated to grow to approximately USD 574.63 billion by 2030. This represents a compound annual growth rate (CAGR) of 5.59% from 2021 to 2030. The cost-effectiveness of generic drugs, which account for 70 to 80% of the retail market, makes them a preferred alternative to branded medications. With India's population expanding, particularly the aging demographic, there has been a notable increase in the demand for generic medicines due to their affordability and comparable effectiveness to branded drugs.

The global demand for affordable healthcare solutions has surged, and India’s generics sector has risen to meet this need. Indian pharmaceutical companies are renowned for their ability to produce high-quality generic drugs at a fraction of the cost of their branded counterparts. This affordability is particularly significant in developing countries where access to essential medications is often limited by high costs. By providing cost-effective alternatives, Indian generics have played a crucial role in increasing global access to medications, thus solidifying India’s reputation as the “pharmacy of the world.”

It has significantly driven revenue growth for domestic pharmaceutical companies. With an expanding portfolio of generic drugs, these companies have been able to tap into new markets and broaden their revenue streams. This growth is further amplified by the robust export of generics to developed markets such as the United States and Europe, where Indian pharmaceutical firms have secured substantial market shares. The ability to penetrate these high-value markets highlights the global competitiveness of Indian generics.

Additionally, the generics boom has led to increased investment in research and development (R&D) within the Indian pharmaceutical sector. While generics are typically less research-intensive than innovative drugs, the competitive nature of the global generics market has spurred Indian companies to invest in R&D for improving manufacturing processes and developing complex generics, such as biosimilars. This investment not only enhances the capabilities of Indian pharmaceutical firms but also drives technological advancements within the industry.

The rise of the generics industry has also contributed to the overall accessibility and affordability of healthcare in India. By providing lower-cost medication options, the generics sector helps reduce the financial burden on Indian patients, particularly those in lower-income brackets. This increased accessibility is crucial in a country where a significant portion of the population faces economic constraints that impact their ability to afford healthcare services. The National Pharmaceutical Pricing Authority (NPPA) in India operates under a government resolution to regulate medicine prices, ensuring their availability, affordability, and economic accessibility. It is now an affiliated office of the Department of Pharmaceuticals within the Ministry of Chemicals and Fertilizers. Established as an expert body, the NPPA is responsible for setting and updating prices for bulk drugs and formulations listed under the Drugs (Prices Control) Order. Additionally, it oversees the pricing of decontrolled drugs and formulations.

Key Market Challenges

Quality Control and Counterfeiting

The Indian pharmaceutical market stands as a global powerhouse, known for its significant contributions to generic drug manufacturing and affordable healthcare solutions. However, it faces a formidable challenge in the realm of quality control and counterfeiting. These issues are not merely regulatory hurdles but are deeply intertwined with the market’s integrity and the health of millions of consumers.

Quality control is a cornerstone of any pharmaceutical industry, essential for ensuring that drugs are safe, effective, and meet specified standards. In India, the complexity of maintaining stringent quality control is amplified by several factors. The market is characterized by its vast scale and the sheer volume of products manufactured and distributed. This scale often strains the existing regulatory frameworks and enforcement mechanisms. The Indian pharmaceutical sector comprises numerous small and medium-sized enterprises (SMEs) alongside large multinational corporations. While large companies typically have robust quality control systems, SMEs may struggle with the resources needed to maintain high standards, leading to potential discrepancies in product quality.

The regulatory environment, overseen by the Central Drugs Standard Control Organization (CDSCO) and state-level authorities, has made strides in tightening quality controls. However, the enforcement of these regulations remains inconsistent. The approval process for new drugs and manufacturing practices can be protracted, and frequent updates to regulatory requirements can be challenging for companies to keep pace with. This inconsistency can lead to gaps in compliance, making it easier for substandard products to enter the market.

Counterfeiting poses an even more severe threat to the pharmaceutical sector in India. The proliferation of counterfeit drugs undermines public trust and poses grave health risks. These counterfeit products often enter the supply chain through various channels, including unregulated distributors and inadequate monitoring at the retail level. The financial allure of counterfeiting, driven by the high profitability of imitation drugs, further exacerbates the problem. Counterfeit drugs can range from entirely fake products to those that are contaminated or contain incorrect dosages, making them a serious health hazard.

According to a report by Express Pharma published in January 2023, counterfeiting is most prevalent in the FMCG, apparel, and agrochemical sectors, accounting for approximately 30 percent of instances. This is followed by the pharmaceutical, automotive, and consumer durables sectors, which experience counterfeiting rates of 20 to 25 percent. The report highlights that nearly 27 percent of consumers were unaware they had purchased counterfeit products at the time of purchase. This underscores the urgent need to enhance awareness and educate consumers on how to identify counterfeit goods. The top sectors where consumers most frequently encounter counterfeit products are apparel (31 percent), FMCG (28 percent), and automotive (25 percent), followed by pharmaceuticals (20 percent), consumer durables (17 percent), and agrochemicals (16 percent).

Efforts to combat counterfeiting include enhanced surveillance and the adoption of advanced technologies such as serialization and anti-counterfeiting measures. Serialization involves assigning a unique serial number to each package, which can be tracked throughout the supply chain to ensure its authenticity. Despite these efforts, the sheer scale of the Indian pharmaceutical market and the sophistication of counterfeit operations pose ongoing challenges.

Key Market Trends

Growing Demand of Biopharmaceuticals

The Indian pharmaceutical industry is witnessing a transformative shift, with biopharmaceuticals emerging as a significant growth driver. This trend reflects a broader global movement towards biologics and advanced therapies, underscoring India's evolving role in the international pharmaceutical landscape. The increasing demand for biopharmaceuticals is reshaping the industry, driven by a confluence of factors that highlight both opportunities and challenges.

Biopharmaceuticals, which encompass a range of products including monoclonal antibodies, vaccines, and gene therapies, are distinguished by their complex production processes and therapeutic innovations. Unlike traditional small-molecule drugs, biopharmaceuticals are derived from biological sources and involve intricate manufacturing techniques. This complexity is matched by their efficacy in treating a wide array of diseases, including cancer, autoimmune disorders, and rare genetic conditions.

India has demonstrated that an emerging economy can become a leading player in the critical biopharma sector, developing drugs and vaccines for diseases prevalent in developing nations. The National Biopharma Mission (NBM) has been operational in India, supported by the World Bank-financed Innovate in India for Inclusiveness Project. This initiative facilitates collaboration among public, private, and academic institutions to address and overcome barriers that have been impeding innovation in the sector.

One of the primary catalysts for the growing demand for biopharmaceuticals in India is the increasing prevalence of chronic and lifestyle-related diseases. India is experiencing a rise in conditions such as diabetes, cardiovascular diseases, and cancer, which require advanced treatment options. Biopharmaceuticals offer targeted therapies that address these diseases with greater precision, improving patient outcomes and quality of life. This shift towards personalized medicine aligns with the global trend towards more effective and tailored treatments.

According to a report published by BioSpectrum in August 2024, the Indian economy has experienced substantial growth in recent years and is expected to expand at a rate of 7% over the next two years. The BioEconomy sector, in particular, has demonstrated significant potential. In 2020, the Indian BioEconomy sector achieved a notable growth rate of 14.1%, contributing approximately 2.6% to India's GDP. The sector was valued at USD 80.12 billion in 2021, up from USD 70.2 billion in 2020. As a major global supplier of affordable drugs and vaccines and home to over 5,000 startups, the Indian BioEconomy sector is projected to reach a value of USD 300 billion by 2030.

Another significant factor contributing to the rise of biopharmaceuticals in India is the robust growth of the biotechnology sector. Indian pharmaceutical companies are investing heavily in biotechnology research and development, recognizing the potential for biopharmaceuticals to drive future growth. This investment is supported by a favorable regulatory environment, as the Indian government is actively promoting biopharmaceutical innovation through policies and incentives. The introduction of the National Biotechnology Development Strategy aims to enhance the sector’s capabilities and foster collaboration between research institutions and industry players.

The growing focus on biosimilars is also playing a crucial role in the expansion of biopharmaceuticals in India. Biosimilars, which are biologic products highly similar to an already approved reference product, offer a cost-effective alternative to expensive biologic therapies. The Indian pharmaceutical industry is well-positioned to leverage its expertise in generics to develop and market biosimilars, thereby increasing access to essential biologic treatments. This not only meets domestic healthcare needs but also strengthens India’s position in the global biopharmaceutical market.

Segmental Insights

Type Insights

Based on Type, Pharmaceutical Drugs have emerged as the fastest growing segment in the India Pharmaceutical Market in 2024. One of the primary factors fueling the growth of pharmaceutical drugs in India is the country’s expanding healthcare needs. India is experiencing a demographic shift with a growing population and increasing life expectancy, which results in a higher prevalence of chronic diseases such as diabetes, cardiovascular conditions, and cancer. These conditions create a rising demand for effective pharmaceutical interventions. Additionally, the country faces a significant burden of infectious diseases, including tuberculosis and malaria, further driving the need for pharmaceutical solutions.

The growing prevalence of non-communicable diseases (NCDs) has led to an increased focus on long-term treatment regimens and management strategies. Pharmaceutical drugs play a critical role in managing these chronic conditions, leading to an expansion in their usage and, consequently, an increase in market growth. The need for new and improved drugs to address these health challenges is a significant factor in the growing demand for pharmaceutical products.

The Indian pharmaceutical market is witnessing a surge in drug innovations and advancements, contributing to its rapid growth. Pharmaceutical companies in India are increasingly investing in research and development (R&D) to discover novel therapies and enhance existing treatments. The country’s focus on biotechnology and advanced drug delivery systems has led to the development of new drugs that offer more effective solutions for a variety of health conditions.

India’s pharmaceutical firms are making significant strides in developing generic drugs, biosimilars, and complex formulations. The emphasis on high-quality generics has enabled the country to cater to both domestic and international markets, providing affordable and accessible treatment options. The introduction of cutting-edge therapies, such as targeted therapies and immunotherapies for cancer, has further spurred market growth by offering innovative solutions to previously hard-to-treat conditions.

Drug Classification Insights

Based on Drug Classification, Generic Drugs have emerged as the dominating segment in the India Pharmaceutical Market during the forecast period. A significant factor in the rise of generic drugs is the favorable regulatory environment established by India’s Patents Act of 1970. This legislation allowed the production of generic versions of patented drugs, which fundamentally transformed the pharmaceutical industry. The Act was designed to promote affordable healthcare by enabling domestic manufacturers to produce and market cheaper alternatives to branded medications. This regulatory framework has been pivotal in establishing India as a global leader in the generic drug sector, providing a competitive advantage that has spurred extensive growth and innovation within the industry.

India’s burgeoning population, particularly its aging demographic, has amplified the demand for affordable healthcare solutions. The rising prevalence of chronic conditions such as diabetes, hypertension, and cardiovascular diseases requires long-term medication, which increases the need for cost-effective options. Generics offer a viable solution, providing essential drugs at lower prices without compromising on quality. The expanding middle class and increasing healthcare access further fuel the demand for generics, as more people seek affordable medication options.

India’s prowess in the generic drug sector is not confined to the domestic market. The country has become a major exporter of generics, supplying a significant portion of the world’s generic medications. This global integration has reinforced the position of Indian generics, with Indian pharmaceutical companies establishing a strong presence in international markets. The ability to offer high-quality generics at competitive prices has enabled Indian firms to capture substantial market shares in developed countries, further enhancing the industry’s growth and influence.

Despite their lower cost, Indian pharmaceutical companies have made substantial investments in research and development to enhance the quality and efficacy of generic drugs. This commitment to innovation has led to the development of complex generics and biosimilars, which cater to specialized medical needs and offer additional revenue streams for companies. Technological advancements in manufacturing processes have also improved efficiency and cost-effectiveness, reinforcing the competitive edge of Indian generics.

Regional Insights

Based on Region, West India have emerged as the dominating region in the India Pharmaceutical Market in 2024. West India, particularly the states of Maharashtra and Gujarat, benefits from a well-developed industrial infrastructure that has significantly contributed to its dominance in the pharmaceutical market. Maharashtra, with Mumbai as its commercial hub, offers a thriving ecosystem for pharmaceutical companies. The city is home to a substantial number of multinational corporations (MNCs) and domestic pharmaceutical firms, drawn by its advanced infrastructure, availability of skilled talent, and proximity to major ports. This geographical advantage facilitates efficient import and export operations, essential for global pharmaceutical trade.

Gujarat, another key player in West India, has emerged as a pharmaceutical powerhouse due to its conducive business environment and government policies that favor industrial growth. The state government has implemented several initiatives to attract pharmaceutical investments, including offering incentives for setting up manufacturing units and research facilities. Gujarat's well-established chemical and pharmaceutical industrial parks, such as the Gujarat Industrial Development Corporation (GIDC) estates, provide companies with the necessary infrastructure and logistical support to thrive.

The presence of a strong network of research and development (R&D) facilities further cements West India’s position in the pharmaceutical sector. The region is home to numerous R&D centers and institutions that foster innovation and support pharmaceutical development. Collaboration between academia and industry in West India has led to significant advancements in drug development and manufacturing processes. The region's focus on R&D is crucial in maintaining a competitive edge in the global pharmaceutical market, particularly in the development of generic drugs and specialty pharmaceuticals.

Key Market Players

• Sun Pharmaceutical Industries Limited
• Divis Laboratories Limited
• Cipla Limited
• Dr. Reddy’s Laboratories Limited
• Torrent Pharmaceutical Limited
• Zydus Lifesciences Limited
• Abbott India Limited
• Alkem Laboratories Limited
• Biocon Limited
• Lupin Limited
• Mankind Pharma Limited
• Intas Pharmaceuticals Limited
• Piramal Enterprises Limited
• Wockhardt Limited
• Glenmark Pharma Limited

Report Scope

In this report, the India Pharmaceutical Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

India Pharmaceutical Market, By Type:

• Pharmaceutical Drugs
• Biologics

India Pharmaceutical Market, By Drug Classification:

• Branded Drugs
• Generic Drugs

India Pharmaceutical Market, By Mode of Purchase:

• Prescription-Based Drugs
• Over-the-counter Drugs

India Pharmaceutical Market, By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

India Pharmaceutical Market, By Region:

• North India
• East India
• West India
• South India

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Pharmaceutical Market.

Available Customizations:

India Pharmaceutical Market report with the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.